Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So, there was 1.6M in warrants converted then.
The 250K and 175k both showed up as buys I already said I don't trust OTC buys and sells very much.
I don't really care too much once the PR is released none of this jocking for position will matter.
A 250K and 175K buy/sell @.20...hmmm.
Don't know she might just not like me Won't hurt for someone else to give it a whirl number is: 303-282-4800
I just called the T/A and either they are tired of me calling since it's the same women answering or something else because...... This time she said "You will have to call the CEO" I asked why is that there is no gag order and her reply was "Because I wasn't a institional investor I would have to call the CEO"
Not very happy with that.
Your mystichrome sig is way too big and considering the terminator was first affordable by middle aged men who have now moved on to Z06's, 911TT's, Ford GT's, etc I don't know if I agree with it
Pretty crazy!!
We really don't need to reference the Urotoday article anymore. It was posted on Friday and now today that's probably good enough.
See what biotech has for today DSCO, PWRM, HDVY, all moved nice on Friday. DSCO Thurs and Friday.
The big news is CIT filed BK many people stuck in that now............back to HDVY is today PR day that would be awesome!!
Glad you did too Nebula.
Good bit of data Ren, thanks for digging that up! I love stuff like that.
O/S VERIFIED 10/30 169M NO CHANGE
Like this chart?
Looking nice alot of biotechs moving today good day to be in the sector. Some news Monday would be awesome!!
True.
I don't know. I may try to call the new IR company I haven't talked to them yet. I know results should be out anytime from previous conversations though. The urine test will be succesfful and will be commercialized.
It has left all of the biotechs!! There isn't a biotech penny moving at the moment all of them are down alot. I'm actually encouraged because HDVY is holding in the low .20's and with news around the corner the MOJO will be back and hopefully for good.
O/S update tom.
Yes, bobabett was saying how the MM's were going to let it run and then dropped the bid and the ask for some reason. I disagreed and said you need buyers at the ask for a run and HDVY doesn't have a ton of those at the moment.
I posted the last 11-12 minutes to show at the end of the day it was 50/50 buy/sell and over 25% of the volume happened in the last 11 minutes!! There was no holding back by the MM's there just wasn't alot of buy volume.
141566 traded in the last 11 minutes.
There is no let it run without buyers and there were no buyers here is the tale of tape. Until news hits or biotech makes a correction I see this churning and that's it.
Time & Sales
Price Size Exchange Time
0.225 2777 OBB 15:59:47
0.21 10000 OBB 15:59:45
0.22 200 OBB 15:59:41
0.22 5600 OBB 15:59:40
0.21 2554 OBB 15:59:39
0.225 8000 OBB 15:59:35
0.21 5000 OBB 15:57:46
0.21 5000 OBB 15:56:50
0.21 5000 OBB 15:56:47
0.21 5000 OBB 15:56:40
0.222 435 OBB 15:56:32
0.21 5000 OBB 15:56:32
0.21 5000 OBB 15:56:31
0.222 5000 OBB 15:56:30
0.22 5000 OBB 15:55:54
0.22 5000 OBB 15:55:46
0.22 5000 OBB 15:55:35
0.22 5000 OBB 15:55:30
0.222 5000 OBB 15:54:04
0.222 5000 OBB 15:54:01
0.225 5000 OBB 15:52:58
0.225 5000 OBB 15:52:09
0.235 3000 OBB 15:51:56
0.226 10000 OBB 15:51:44
0.235 4500 OBB 15:51:09
0.235 4500 OBB 15:50:32
0.226 5000 OBB 15:50:28
0.226 5000 OBB 15:49:53
0.23 5000 OBB 15:49:27
Always good to see you post. I've copied many of your previous posts here in the past thanks for posting your opinion.
This isn't meant to be exhaustive by any means I just wanted to show how ridiculous OTC's comment are on the Yahoo board. These are few tidbits from current R&D facilities/companies that are using urine for various prostate cancer detection either to be used with PSA or without, to detect malignancy, severity, or just detection in general. None of the preliminary studies would hold a candle to the numbers that HDVY's gene set has produced in efficacy or accuracy and none of these companies have the weight of Quest or Abbott behind them. It's like comparing Quicky Mart to WalMart. The common theme here is the use of a DRE which will almost certainly be used in HDVY's test. Don't believe the bull that is spewed by flippers and traders the longs will be rewarded. Don't forget to read the last part too. These are all seperate studies/tests 1 in bold, italic, then underlined.
Prostate cancer biomarkers are enriched in urine after prostatic manipulation, suggesting that whole cells might also be detectable for diagnosis. We tested multiplex staining of urinary sediments as a minimally invasive method to detect prostate cancer. Urine samples were collected from 35 men who had prostatic massage (attentive digital rectal examination) in a urology clinic and from 15 control men without urologic disease and without massage, for a total of 50 specimens (27 cancer-positive cases and 23 cancer-negative cases). LNCaP prostate cancer cells spiked into urine were used for initial marker optimization. Urine sediments were cytospun onto glass slides and stained. Multiplex urine cytology was compared with conventional urine cytology for cancer detection; anti–α-methylacyl-CoA racemase antibody was used as a marker of prostate cancer cells, anti-Nkx3.1 as a marker of prostate epithelial cells, anti-nucleolin as a marker of nucleoli, and 4′-6-diamidino-2-phenylindole to highlight nuclei. Prostate cancer cells were successfully visualized by combined staining for α-methylacyl-CoA racemase, Nkx3.1, and nucleolin. Of the 25 informative cases with biopsy-proven prostate cancer, 9 were diagnosed as suspicious or positive by multiplex immunofluorescence urine cytology, but only 4 were similarly judged by conventional cytology. All cases without cancer were read as negative by both methods. The multiplex cytology sensitivity for cancer detection in informative cases was 36% (9/25), and specificity was 100% (8/8). In conclusion, we have successfully achieved multiple staining for α-methylacyl-CoA racemase, Nkx3.1, nucleolin, and 4′-6-diamidino-2-phenylindole to detect prostate cancer cells in urine. Further refinements in marker selection and technique may increase sensitivity and applicability for prostate cancer diagnosis.
The PCA3 test is performed on prostate cells loosened during a digital rectal examination (DRE) and then washed out by urine. The assay is designed to detect a certain gene that is highly overexpressed in prostate cancer cells.
DD3 was initially described in 1994 at the Congress of the European Society for Urolological Oncology and Endocrinology in Berne, Switzerland. Further development of PCA3 was performed in the laboratories of Jack A. Schalken, Bussemakers’ supervising professor at University Hospital, Nijmegen, the Netherlands. Among the important contributions from Nijmegen were the first clinical demonstration of the specificity of PCA3, its measurability in urine, and the importance of denoting PCA3 expression vis-á-vis a background of normal prostate epithelial genetic material.5,6 Interest in urinary prostate cells, which had been generally abandoned years before, was then resurrected, and urinary PCA3 research studies were soon instituted by Yves Fradet in Laval University in Canada. A prototype urine assay known as uPM3 was developed at DiagnoCure. During this time, the nomenclature for DD3 was formally changed to PCA3.
Purpose: We assess the feasibility of a urinary test for prostate cancer detection in a high-risk patient cohort based on methylation-specific PCR analysis of the π class glutathione S-transferase (GSTP1) gene promoter.
Experimental Design: A total of 45 men underwent transrectal ultrasound-guided biopsy of the prostate for suspected malignancy. Clean-catch voided urine specimens were prospectively collected from each patient immediately after biopsy. Genomic DNA was isolated from urine specimens and subjected to sodium bisulfite modification. Methylation of the GSTP1 promoter was examined in a blinded manner by methylation-specific PCR analysis and correlated with pathology results, and clinical information was obtained from the patient record.
Results: Methylation of GSTP1 in the urine was detected in a total of 18 of 36 (50%) informative cases. A total of 7 of 18 (39%) patients with prostate adenocarcinoma identified on their initial biopsy had detectable urinary GSTP1 methylation (58% sensitivity among informative cases). Abnormal urinary GSTP1 methylation was also detected in 7 of 21 (33%) patients without evidence of cancer on biopsy and in 4 of 6 (67%) patients diagnosed with atypia or high-grade prostatic intraepithelial neoplasia.
Conclusions: We have demonstrated the feasibility of a novel, noninvasive molecular approach for the detection of epigenetic changes associated with prostate cancer. A screening test based on GSTP1 methylation in the urine specimens of patients with suspected prostate malignancy may be a useful adjunct to serum screening tests and digital rectal examination findings for identification of men at increased risk of harboring cancer despite a negative biopsy. This molecular assay has potential application for stratification of patients into low- and high-risk groups for surveillance versus repeat biopsy.
Besides this we have the following to look forward too.
HDC's key license partners to date include Abbott Laboratories (ABT, Trade ), Quest Diagnostics (DGX, Trade ), Clarient Inc. (CLRT, Trade ) and Pfizer Inc. (PFE, Trade ).
HDC recently entered into royalty-bearing licenses for its new urine-based prostate cancer test with Quest Diagnostics Incorporated and Abbott Laboratories for development and commercialization. These licenses are solely for the use of HDC's prostate cancer biomarkers in urine.
HDC also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories and Clarient Inc. for development and commercialization. This license is solely for the use of HDC's prostate cancer biomarkers in tissue biopsy specimens.
HDC has also partnered with Pfizer Inc. for use of HDC's SVM and SVM-RFE pattern recognition technology in Pfizer's global research and development.
HDC has also entered into a license with Smart Personalized Medicine, LLC ("SPM"), a privately-held company, founded by Dr. Richard Caruso, Chairman and founder of Integra Life Sciences (NasdaqGS: IART) to develop a superior breast cancer prognostic test using HDC's SVM technology in cooperation with MD Anderson Cancer Center. HDC has a fifteen percent equity position in SPM and HDC will receive royalties from this new breast cancer prognostic test.
HDC has entered into a development and license agreement with DCL Medical Laboratories, LLC, for the collaborative development and commercialization of SVM-based computer assisted diagnostic tests for the independent detection of ovarian, cervical and endometrial cancers.
HDC's Patents Cover Non-Medical Applications
There are a large number of non-medical applications protected by HDC's patents, including but not limited to, fraud detection, investment and commodities price predictions, bankruptcy prediction, image and object analysis, face recognition, text and document classification, speech recognition, personalized consumer purchasing patterns, decryption, vehicle control and monitoring, weather forecasting and database marketing
1) That's not correct Rem. all of the warrants can be exercised below the current share price. All of them expire within 7m-2years pre Tobin he has restrictions. I've already stated the original investors here will not be selling for pennies and who would attempt to exercise with the share price at .22? You could not sell 1-2 Million now with the bid price dropping below the exercise price they would lose money. The stock price would have to be in the $1-2 range to try to sell millions of shares. Who would take that risk?
2)OTC, is long time flipper dual personality poster who is positive or negative depending on the lunar charts. Like OneCher said who's working on this Abbott/Quest!! Why would they try if it was that simple? Medicine is about breaking boundaries and opening doors. There are a few studies proving urine is the most sensitive substance in the human body. I'll retort his ask yourself this question with my own.
**Would Abbott have given HDVY 100K for pre work for nothing?
**Would Abbott/Quest have taken the time effort to draw up contracts and fee schedules for nothing.
**Company states they were pleased with the progress in the last filing.
**This is from Quest in March "In addition, we are excited by results of a study related to prostate cancer conducted by our oncology diagnostics team at Nichols Institute. While more research is needed, these data may help us to eventually develop a noninvasive test for differentiating patients with prostate cancer from those who have benign prostate hyperplasia, a common condition whose symptoms can mimic cancer," Dr. albitar said.
**Any urine test will more than likely be accompanied with a DRE first.
3/4) News is needed OTC stocks don't stay on fire for long. HDVY did go up over 500%+ depending where you want to start from and is holding right now. Waiting for news!! The stock encompassed more traders and flippers this run than in that last 5 years and seems to be basing here. As long as the big news we are all waiting for comes soon and MOMO juice is still warm this will run very hard. Volatility will be there for that move up too ther will come a point where HDVY leaves the OTC bullcrap....that point is a few deals a way though.
I recommend call Tobin or Barnhill email IR the company isn't afraid to talk to investors.
GLTA.
I can't see it dropping much more that would be pretty insane. I'm gonna add here.
I'll continue to harp on that 1.5M shares paid to push the stock. You don't push a stock unless you have shares to sell and looking at the PPS someone is selling hard.
100 Boardmarks as of last night the more the merrier when this really starts to move.
I did a quick 15 minute google search and didn't find anything bylo. Any other details you could provide that may help us in the search? I'll be the first to say my mind isn't what it used to be especially in the middle of the night.
Maybe someone else has the answer?
HDVY does not release PR's often....I'm sure you know that though.
We all have theories most of us are thinking anytime between now and the end of Nov. if the timeline holds true. With the recent events I believe Quest is on schedule.
I sent you a PM Chazzy. The theme is one step at a time with my theory on what could happen down the road. I still stand by $1 minimum with a successful trial PR and much higher with a Prostate test launch PR.
Good for you!!
Looks like it will be a very low volume day. Many of the traders dumped yesterday, some got in for a bounce yesterday mid-day and most sold at the close going by the sells that went off towards the end of the day.
I doubt we will see much today.
Rem, there is a filing September 18th. I've already given my .02 to a few people that have asked questions about the warrants. The people who invested in this company are not going to be selling for pennies like a typical OTC trader would think.
To me it just proves that big news is on it's way!!
I will be calling the TA every Friday to verify the O/S and that will tell the story. I'll say it now I doubt you will see any change at all, but I will post the O/S no matter what.
Yep, 1.5 Million shares in promotion, makes you wonder if they have shares to sell?
1 or 2 people read the board today!! #38 most read on IHUB!!
http://investorshub.advfn.com/boards/most_read.aspx
Bounce looking good.
Would be a slap in the face to the sellers if this closed practically unchanged.
Doubt it seriously. I'll be confirming the O/S on Friday's. The warrants are even more of a tell tale sign that something huge is coming (Prostate test) they are at .14 and .19 and the company get's all the proceeds.
You couldn't sell 2 Million shares right now and not have fall the share price fall below .19. They are registered for sale IMO because huge news is coming and then they may be exercised.
Looks like that's about it some buying coming in now.
We just had our first buy in the last 200K traded. If that ratio continues argh.